Answers are grounded in this paper and cite their sources.
This study examines the pharmacokinetics of tolfenamic acid in Pekin ducks, revealing dose-dependent effects on bioavailability and plasma protein binding.
This study aimed to examine the pharmacokinetic changes in tolfenamic acid administered intravenously and orally to ducks at different doses (2, 4, and 8 mg/kg). Furthermore, the binding ratio to plasma proteins was assessed utilizing the ultrafiltration method. Eighteen male Pekin ducks were randomly assigned to three dosage groups (2, 4, and 8 mg/kg), with each group undergoing a trial in two phases: intravenous (IV) and oral administration. The sample was analyzed using an approved HPLC-UV method. A non-compartmental analysis was utilized to evaluate the pharmacokinetic data. For 2 mg/kg IV injection, the area under the curve from zero to infinity (AUC0-∞), total clearance (ClT), volume of distribution at steady state (Vdss), and elimination half-life (t1/2ʎz) were 13.03 h*µg/mL, 0.15 L/h/kg, 0.30 L/kg, and 1.72 h, respectively. Following oral administration at a dose of 2 mg/kg, the AUC0-∞, peak plasma concentration (Cmax), and bioavailability were 6.32 h*µg/mL, 2.25 µg/mL, and 48.52%, respectively. The t1/2ʎz was extended, Cmax and AUC0-∞ elevated, Tmax shortened, and ClT decreased in a dose-dependent manner. No dose-related change was observed in Vdss and bioavailability. In ducks, tolfenamic acid’s plasma protein binding was 99.74%, unaffected by concentration. These results may contribute to the application of tolfenamic acid in ducks at different doses, but dose-related changes in therapeutic efficacy should also be demonstrated.
No takes yet. Share an insight, caveat, or question.
Çorum et al. (2025) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: